Bristol-Myers Squibb Company today reported strong financial results for the third quarter of 2014, adjusted 2014 GAAP guidance and confirmed 2014 non-GAAP guidance. The quarter was highlighted by strong performance by key brands, significant data and regulatory milestones for Opdivo , the launch of the company's hepatitis C regimens in Japan and Europe and the completion of several business development transactions supporting the company's oncology portfolio.